Glaxo Signs Oncology Deal With Adaptimmune Worth USD350 Million
LONDON (Alliance News) - UK based biotechnology company Adaptimmune Ltd confirmed Monday that it had entered into a collaboration and licensing agreement with pharmaceutical giant GlaxoSmithKline PLC worth a potential USD350 million over the next seven years, for its cancer programme. Under
Read more